Clinical Trials Logo

Gastric Intestinal Metaplasia clinical trials

View clinical trials related to Gastric Intestinal Metaplasia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05345314 Completed - Clinical trials for Gastric Intestinal Metaplasia

Endoscopic Grading of Intestinal Metaplasia

Start date: March 1, 2022
Phase:
Study type: Observational

Long-term Helicobacter pylori infection causes premalignant gastric conditions, such as atrophic gastritis and intestinal metaplasia. Image-enhanced endoscopy techniques such as narrow-band imaging (NBI) and magnifying endoscopy improve the diagnosis of gastric intestinal metaplasia (GIM). However, there are no comparative data on the utility of NBI and magnifying endoscopy for diagnosing GIM.

NCT ID: NCT05288153 Completed - Clinical trials for Gastric Intestinal Metaplasia

Metformin Efficacy and Safety for Gastric Intestinal Metaplasia

Start date: April 1, 2022
Phase: Phase 4
Study type: Interventional

Gastric intestinal metaplasia significantly increases the risk of gastric cancer. Metformin, a biguanide, which is widely used for treating diabetes mellitus, has recently been suggested to have a suppressive effect on tumorigenesis and cancer cell growth. The investigators devised a prospective randomized controlled trial to evaluate the chemopreventive effect of metformin against gastric intestinal metaplasia and the safety of this drug in non-diabetic gastric intestinal metaplasia patients.

NCT ID: NCT04348266 Completed - Treatment Clinical Trials

RFA for GIM Treatment

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

Use radiofrequency ablation (RFA) for Gastric intestinal metaplasia (GIM) treatment.

NCT ID: NCT03672708 Completed - Clinical trials for Gastric Intestinal Metaplasia

Confocal Laser Endomicroscopy With Cresyl Violet for in Vivo Diagnosis of Gastric Intestinal Metaplasia

Start date: September 16, 2018
Phase: N/A
Study type: Interventional

Confocal laser endomicroscopy (CLE) is a novel endoscopic system which can provide approximately 1000-fold magnification of the gastrointestinal mucosa. Previous studies have demonstrated its diagnostic value for Gastric intestinal metaplasia (GIM) with the use of a contrast agent.Recently, Cresyl violet (CV) has been used in CLE to visualize tissue architecture in human ileum, colon or myenteric plexus.No investigation has reported the characterization of GIM imaged with CLE when using CV as staining dye

NCT ID: NCT02846688 Completed - Clinical trials for Gastric Intestinal Metaplasia

Gene Expression Profiling in Human Gastric Intestinal Metaplasia Mucosa and Duodenal Mucosa

Start date: September 2014
Phase: N/A
Study type: Observational

To analyze the genome pattern in human gastric Intestinal Metaplasia Mucosa and duodenal Mucosa.

NCT ID: NCT01945177 Completed - Gastric Cancer Clinical Trials

RCT: WLE vs. NBI in Upper Gastrointestinal Endoscopy

Start date: January 2012
Phase: N/A
Study type: Interventional

It is recognized that gastroscopy can miss intestinal metaplasia, dysplasia and early gastric cancer. This could conceivably be due to the fact that these lesions may only present as subtle mucosal changes on conventional white light endoscopy (WLE) and thus be easily missed. In narrow band imaging (NBI) a rotating interference narrow band filter is interposed after the xenon light source such that when the NBI mode is switched on, discrete blue and green wavelengths are used and this improves mucosal surface contrast and facilitates visualization of mucosal details. A new NBI system is available that allows brighter illumination. We hypothesize that bright -NBI is superior to WLE in detecting focal gastric lesions such as gastric intestinal metaplasia, dysplasia and early gastric cancer in subjects undergoing gastroscopy.

NCT ID: NCT01489397 Completed - Clinical trials for Gastric Intestinal Metaplasia

Magnified Intelligence Chromoendoscopy Plus Probe-based Confocal Laser Endomicroscopy for Gastric Intestinal Metaplasia Diagnosis

Start date: April 2010
Phase: N/A
Study type: Interventional

Magnified intelligence chromoendoscopy (FICE) plus probe-based confocal laser endomicroscopy (pCLE) for Gastric Intestinal Metaplasia (GIM) diagnosis: a feasibility trial Research Question: Is confocal endomicroscope feasible to diagnose gastric intestinal metaplasia? Objective: To evaluate the feasibility of confocal endomicroscope in diagnose gastric intestinal metaplasia. Hypothesis: Confocal endomicreosocpe can provide the accurate diagnosis of gastric intestinal metaplasia. Research design: Diagnostic study Sample size: The investigators follow the population in recent study from Imraporn et al.: Validity of magnify NBI for gastric intestinal metaplasia targeted biopsy (N= 50) Data analysis: Confocal Barrett's esophagus classification was used to evaluate agreement of confocal endomicroscopic finding in gastric intestinal metaplasia. The accuracy of new criteria for GIM by confocal endomicroscope was evaluated in relation to pathological report, a gold standard for diagnosis, and reported as sensitivity, specificity, positive predictive value, negative predictive value and accuracy of these criteria. Expected Benefit and Application: The feasibility of confocal endomicroscopy for diagnosis gastric intestinal metaplasia in order to improve the quality of GIM/dysplasia/early gastric cancer detection and then decrease the mortality rate from gastric cancer in the future.

NCT ID: NCT01384201 Completed - Clinical trials for Gastric Intestinal Metaplasia

Confocal Endomicroscopy Detection of Gastric Preneoplasia and Neoplasia

R-CE-GCEP
Start date: August 2007
Phase: N/A
Study type: Observational

This is a prospective randomised study investigating the use of chromoendoscopy and confocal laser endomicroscopy for the detection of preneoplastic neoplasm in patients at high-risk of gastric cancer.